Mortality within 30 days of receiving systemic anti‐cancer therapy at a regional oncology unit: What have we learned?

Yoong, Jaclyn; Seah, Jo-An; Hamilton, Kate; Teo, Lee Na; Chong, Geoffrey

doi:10.1111/j.1743-7563.2011.01498.x

Cited by 16 publications

(41 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our audit demonstrated the feasibility of 30‐day mortality as an indicator for accessing quality in real‐life practice in a regional outpatient oncology unit in New Zealand. This study is unique as it audited 30‐day mortality over 5 years, as opposed to other contemporary studies, which chose shorter time frames (6–18 months) …”

Section: Discussioncontrasting

confidence: 68%

“…Studies in Japan, UK, Australia and the United States have been published in the last decade . These studies were performed in large oncological institutions and demonstrated feasibility.…”

Section: Introductionsupporting

confidence: 67%

“…A recent study from two large academic centres in the United States with regards to 30‐day mortality rates according to tumour streams documented higher 30‐day mortality rates across numerous tumour streams (colorectal: 12%, breast: 9%) . Within Australasia, the most comparable study to ours in terms of population and institutional size reported a 30‐day mortality rate of 3.4%, although this study was smaller in comparison …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Thirty‐day mortality after systemic anticancer treatment as a real‐world, quality‐of‐care indicator: the Northland experience

Ang

Newton

2018

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 68%

“…Studies in Japan, UK, Australia and the United States have been published in the last decade . These studies were performed in large oncological institutions and demonstrated feasibility.…”

Section: Introductionsupporting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Thirty‐day mortality after systemic anticancer treatment as a real‐world, quality‐of‐care indicator: the Northland experience

Ang

Newton

2018

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…included only epithelial malignancies, Kao et al . excluded those with a haematological malignancy, Yoong et al . included all malignancies except acute leukaemia, Earle et al .…”

Section: Introductionmentioning

confidence: 99%

“…restricted inclusion to patients with advanced breast cancer. Most studies only included patients with advanced cancer; however, Yoong et al ., O'Brien et al . and Barbera et al .…”

Section: Introductionmentioning

confidence: 99%

Administration of chemotherapy with palliative intent in the last 30 days of life: the balance between palliation and chemotherapy

Zdenkowski

Cavenagh

et al. 2013

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Prospective analysis of 30‐day mortality following palliative chemotherapy at a tertiary cancer centre

et al. 2018

View full text Add to dashboard Cite

Background Thirty‐day mortality after chemotherapy has been suggested as a marker of quality in oncology care. Retrospective audits worldwide have put this figure at between 8.1% and 43%, with previous retrospective Australian audits putting this figure at between 3.4% and 18%. To date, there has not been a prospective cohort study of patients receiving palliative intent chemotherapy at an Australian chemotherapy day unit. Aim The aim of the study is to benchmark 30‐day mortality for patients receiving palliative intent chemotherapy and identify associated factors at an Australian tertiary cancer centre. Methods and results A prospective cohort study of all patients with a diagnosis of malignancy referred for palliative intent intravenous chemotherapy to the Sunshine Hospital Chemotherapy Day Unit over a 12‐month period. The primary outcome was death within 30 days of receiving palliative intent chemotherapy. Other outcome measures included place of death and whether the patient received an outpatient palliative care referral. A total of 314 patients were enrolled in the study, and 98 patients died within the audit period. Of these, 21 (6.6%) died within 30 days of commencing palliative intent chemotherapy, and 60 (18.8%) died more than 30 days after receiving chemotherapy. Of the 34 patients that were referred, but did not start chemotherapy, 18 (52%) died. Multivariable logistic regression found that patients who received an outpatient palliative care referral and received chemotherapy were more likely to die within 30 days, although these did not reach statistical significance. Conclusion(s) This prospective cohort study demonstrated that 6.6% of patients died within 30 days of the administration of palliative intent chemotherapy; however, none of the prespecified factors were found to be statistically significantly associated with 30‐day mortality.

show abstract

Mortality within 30 days of receiving systemic anti‐cancer therapy at a regional oncology unit: What have we learned?

Cited by 16 publications

References 12 publications

Thirty‐day mortality after systemic anticancer treatment as a real‐world, quality‐of‐care indicator: the Northland experience

Thirty‐day mortality after systemic anticancer treatment as a real‐world, quality‐of‐care indicator: the Northland experience

Administration of chemotherapy with palliative intent in the last 30 days of life: the balance between palliation and chemotherapy

Prospective analysis of 30‐day mortality following palliative chemotherapy at a tertiary cancer centre

Contact Info

Product

Resources

About